{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'assessed at 15 degrees. Intermediate ductions are judged by estimating the light position between', 'these points to the nearest 5 degrees.', 'The monocular ductions of each eye (degrees) will be recorded for adduction, abduction,', 'supraduction and infraduction.', 'Except when strictly unavoidable, the same observer should conduct each duction evaluation for', 'the full duration of the study.', '9.5.2 Quality-of-Life Assessment', 'The GO-QoL questionnaire [C. B. Terwee et al, 1998] will be completed on Day 1 and Weeks 6,', '12, and 24 (or PW) during the Treatment Period, and at Months 7 and 12 (or PW) during the', 'Follow-Up Period.', 'The GO-QoL is a 16-item self-administered questionnaire divided into 2 subsets and used to', 'assess the perceived effects of TED by the subjects on (i) their daily physical activity as it relates', 'to visual function, and (ii) psychosocial functioning. The English version of the questionnaire is', 'included in Section 17.3.', '9.5.3 Pharmacokinetic Measurements', 'Blood samples will be collected in 5 mL serum separator tube (SST) collection tubes to evaluate', 'PK at the following time points: pre- and post-infusion on Day 1 and Weeks 3 and 9 of the', 'Treatment Period; single samples will also be collected at Weeks 1, 4, and 24 (but not PW) of the', 'Treatment Period. Samples will be collected, processed, and stored at > -70\u00b0C - at the site until', 'shipment to the central laboratory', 'will store the', 'samples at > -70\u00b0C until shipment to', 'for PK testing (see Table 6.1).', 'Instructions for processing, handling, storing and shipping of PK samples will be detailed in a', 'laboratory manual that will be provided to each site prior to site initiation. A central laboratory', 'will be used for PK sample analysis.', '9.5.4 Safety Variables', 'Safety will be assessed via AE and concomitant medication use monitoring, immunogenicity', 'testing, physical and ophthalmic examinations, vital signs, clinical safety laboratory evaluations', '(complete blood count, chemistry [including thyroid panel and HbAlc], and urinalysis),', 'pregnancy testing (if applicable), and ECGs. The study will also be monitored by a DSMB.', '9.5.4.1 Adverse Events', '9.5.4.1.1 Definitions', '9.5.4.1.1.1 Adverse Event Definition', 'According to ICH, an AE is any untoward medical occurrence in a subject or clinical', 'investigation subject administered a pharmaceutical product and which does not necessarily have', 'a causal relationship with this treatment. An AE can therefore be any unfavorable and', 'unintended sign (including an abnormal laboratory finding), symptom, or disease temporally', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 85 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'associated with the use of a medicinal (investigational) product, whether or not considered', 'related to the medicinal (investigational) product.', 'Pre-existing conditions that worsen during a study are to be reported as AEs. New findings', 'reported from the on-study ophthalmic examinations will not be reported as AEs if according to', 'the Investigator the abnormalities are related to TED and not considered related to the', 'investigational product.', 'Unchanged, chronic conditions are NOT considered AEs and should not be recorded on the AE', 'pages of the eCRF unless there is a clear exacerbation of a chronic condition.', \"Disease progression can be considered as a worsening of a subject's condition attributable to the\", 'disease for which the study drug is being studied (i.e., TED). It may be an increase in the severity', 'of the disease under study and/or increases in the symptoms of the disease. The development of', 'worsening proptosis may be considered as disease progression and not an AE. Events, which are', 'unequivocally due to disease progression, should only be reported as AEs if they fulfill any of', 'the SAE criteria or are the reason for discontinuation of treatment with the study drug.', '9.5.4.1.1.2 Serious Adverse Event Definition', 'A TEAE, baseline event, or suspected adverse reaction is considered serious if, in the view of', 'either the Investigator or Sponsor, it results in any of the following outcomes:', 'Death. This includes any death that occurs during the conduct of a clinical study,', 'including deaths that appear to be completely unrelated to the study drug (e.g., car', 'accidents).', 'Life-threatening adverse experience. An AE or suspected adverse reaction is considered', 'life-threatening if, in the view of either the Investigator or the Sponsor, its occurrence', 'places the subject at immediate risk of death. It does not include an AE or suspected', 'adverse reaction that, had it occurred in a more severe form, might have caused death.', 'Persistent or significant disability or incapacity.', 'Inpatient hospitalization or prolongation of an existing hospitalization.', 'Congenital anomaly or birth defect.', 'Other medically important event which, according to appropriate medical judgment, may', 'require medical or surgical intervention to prevent one of the outcomes listed above.', 'Surgical procedures or other therapeutic interventions themselves are not AEs, but the condition', 'for which the surgery/intervention is required is an AE and should be documented accordingly.', 'Elective surgeries that require hospitalization and treatment received at an emergency room or', 'similar facility will not be considered as SAEs unless one of the definitions of an SAE listed', 'above is met.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 86 of 118']\n\n###\n\n", "completion": "END"}